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submissions, in 53% of cases a high ICER was reported in the summary of guidance 
as a reason for rejection. In about 30% of these cases, the high drug cost was speciﬁ ed 
as the driver of the high ICER. The lack of a robust economic case was mentioned in 
45% of rejections. Limited evidence of clinical beneﬁ t was shown in 43% of cases. 
Other reasons included inadequate type or quality of clinical data (21%) and non-
acceptance of clinical positioning (11%). In 45% of cases the rejections were largely 
due to economic reasons; 6% of cases were not accepted due primarily to clinical 
reasons and in 49% of rejections the criticisms related to both the economic and 
clinical evidence. Uncertainty in the evidence was reported as a problem in most nega-
tive recommendations. CONCLUSIONS: Only slightly over half of the orphan drug 
HTA submissions to these agencies are explicitly rejected primarily on the basis of a 
high ICER. Most HTA rejections are due to a combined lack of robust economic and 
clinical evidence. This suggests that collecting the right kind of data and presenting a 
solid case that accounts adequately for any uncertainty is at least as important as 
meeting trial endpoints and choosing an optimal price.
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OBJECTIVES: Orphan drugs (ODs) face numerous difﬁ culties in demonstrating their 
value through rigorous HTA processes. HTA bodies may therefore choose to take into 
consideration the special circumstances of treatments for orphan indications, either 
formally or informally. The objective of this study was to examine the decisions made 
on ODs by six English-speaking HTA bodies, and assess potential trends between 
agencies. METHODS: AWMSG, CEDAC, NCPE, NICE, PBAC and SMC HTA web-
sites were searched for completed OD assessments (identiﬁ ed via Orphanet website) 
as of April 2010, and data extracted on the recommendations. Recommendations with 
restrictions were categorised as approvals. Comparisons were made to published 
approval rates for drug submissions as a whole. RESULTS: Of the 71 ODs selected, 
55 were assessed by at least one HTA body. The proportion of positive recommenda-
tions for orphan treatments was lower than published approval rates for general 
(orphan and non-orphan) HTA drug submissions in most bodies. NICE approved 
67% completed OD submissions, versus approximately 87% of drugs overall. 
However, PBAC recommended 60% of ODs compared to 54% of drugs as a whole. 
Decisions also varied substantially between agencies. CEDAC had the highest propor-
tion of rejections (73%), compared to NICE, which rejected 33%. There was also 
variation in decisions made on speciﬁ c treatments. Sutent, for example, with an orphan 
designation for renal cell carcinoma, was accepted by AWMSG, CEDAC and SMC, 
while it received a negative recommendation from NCPE, NICE and PBAC. CON-
CLUSIONS: The willingness to assess ODs varies widely by agency and drug, as do 
resultant approval rates. HTA agencies are far more likely to reject OD submissions 
than non-orphan drugs as a whole. However given the differences in their remit to 
assess ODs, direct comparisons should be interpreted with caution. Further research 
is needed to explore the reasons behind these differences in HTA agency decisions.
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OBJECTIVES: To describe research methods and key issues in the HTA process in 
Europe. METHODS: Representatives from HTA bodies globally were recruited by 
members of the ISPOR HTA SIG Research Methods/Principles Working Group to 
complete a 45-minute on-line survey consisting of 48 items within 4 topics related to 
1) organizational information and process; 2) primary HTA methodologies and impor-
tance of attributes; 3) HTA application and dissemination; and 4) quality of HTA 
including key issues. Data were reported for Europe. RESULTS: The survey was 
completed by 11 European countries including Austria, Denmark, France, Germany, 
Hungary, Italy, The Netherlands, Portugal, Spain, Sweden, and Switzerland. Top 
reasons technologies were evaluated included perceived impact on patient outcomes, 
potential cost, and prevalence of the condition. The most common methodologies used 
were cost/economic analyses, systematic reviews & meta-analyses, clinical trials, mod-
eling, and comparative analyses. The most important attributes (in order) were effec-
tiveness, efﬁ cacy, safety, cost-effectiveness, and budget impact. While quality of life 
was frequently assessed by >74% of European respondents, it was not listed as an 
attribute of top importance. Only 24% repeat/update the assessment at regular inter-
vals. For 82% a different organization makes the ﬁ nal decision on coverage, only 
partially relying on the report. The most common educational background for decision 
makers was physician-specialist. Stakeholders are allowed to review the report and 
are involved in assessments >50% of the time, and in the ﬁ nal decisions ~35% of the 
time. Key issues/trends included early assessment of technologies with mechanism for 
conditional coverage, increasing regional interest in HTA, reassessment/horizon scan-
ning, and link between theory and practice in HTA. CONCLUSIONS: This survey of 
representatives within HTA and reimbursement bodies provides current insight into 
the state of HTA research methods in Europe. Future research could expand the results 
to speciﬁ cally address Eastern European countries, Asia, and other emerging markets.
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OBJECTIVES: To assess the outcomes of NICE’s guidance in totality and different 
disease areas. METHODS: A list of NICE Guidance published between 2007 to the 
end of 2009 was identiﬁ ed using HTAinSite™. We classiﬁ ed these recommendations 
into; ‘recommended’, ‘restricted’ and ‘not recommended’, and calculated the percent-
ages. We then analyzed these recommendations according to disease areas; ‘cardio-
vascular/metabolics’, ‘mental health’, ‘infectious diseases’, muscoskeletal conditions’, 
‘oncology’, and ‘others’. RESULTS: In 2007, NICE assessed 25 drugs, 31 in 2008 and 
18 in 2009. Of these, in 2007 NICE recommended 8 drugs (31%) for all eligible 
patients, restricted 13 (53%), and did not recommend 4 (16%). In 2008, 3 (10%) 
were recommended, 21 (68%) were restricted, and 7 (22%) were not recommended. 
Finally, in 2009, 2 (11%) treatments were recommended, while 11 (61%) received 
restricted recommendations and 5 (28%) were not recommended. Between 2007 and 
2009 NICE completed 7 appraisals in ‘cardiovascular/metabolics’ of which 4 received 
a full recommendation, while in ‘mental health’ 2 out of 2 were fully recommended. 
In contrast, in ‘infectious diseases’, 1 out of 5 was fully recommended. In ‘muscoskel-
etal conditions’ only 1 out of 21 were recommended (17 restricted and 3 not recom-
mended) while in ‘oncology’ only 1 out of 23 received a full recommendation (13 
restricted, 9 not recommended). In the ‘others’ group, 4 out of 12 received a recom-
mendation (6 restricted, 2 not recommended). If manufacturers had not proposed 
Patient Access Schemes (PAS) the proportion of guidance not recommended in 2009 
would be 44%. CONCLUSIONS: Appraisal outcomes have become more restrictive 
over time. Furthermore, low cost primary care therapeutics are more likely to receive 
a positive NICE recommendation than high cost speciality care interventions. 
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OBJECTIVES: Over the last decade the National Institute of Clinical Excellence in 
the UK has published guidelines for health technology assessments (HTA) that includes 
recommendations on health outcomes and cost-effectiveness assessments. In Europe, 
this has opened the opportunity for countries to either propose their own guidelines 
or use the British ones. The ECHOUTCOME project is an interdisciplinary European 
research platform funded by the seventh Framework Program of the European Com-
mission with the aim of designing new European guidelines in Health Outcomes and 
Cost-Effectiveness assessments. METHODS: This three years project is structured in 
three phases. Phase 1 aims to conduct a pan-European survey of HTA organizations 
and health outcomes use in the 27 European countries. Multiple correspondence and 
cluster analyses will be carried out to study the potential similarities and divergences 
across Europe. The objective of Phase 2 is to test the robustness and underlying 
assumptions such as reproducibility, neutrality to risk, constancy of time-trade-off 
rate, utility independence, etc. on QALYs, DALYs and HYEs measures. This testing 
will be conducted in the general population (n = 300 per country) in Belgium, France, 
Italy and UK. Phase 3 aims to propose new approaches in Health Outcomes and 
Cost-Effectiveness analyses. RESULTS: The main deliverable of the ECHOUTCOME 
project will be new European Guidelines for assessing Health Outcomes and conduct-
ing Cost-Effectiveness assessments. Of particular interest will be the recommendations 
on the practical usefulness of QALYs, DALYs and HYEs based on the experimental 
validation of their underlying assumptions. CONCLUSIONS: The ECHOUTCOME 
project is the ﬁ rst European validation study of health outcomes measures. This work 
will produce guidelines for public health decision-making in the 27 European 
countries. The ECHOUTCOME outcomes will enhance the debate and increase the 
understanding that will improve the knowledge of existing Health Outcomes 
and Cost-Effectiveness techniques and will promote new approaches for 
decision-making.
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OBJECTIVES: The popularity and availability of biomarkers has rapidly increased in 
recent years, thanks to innovative advances in pharmacogenomics. Predictive biomarkers 
have high potential value in HTA as they may increase the observed efﬁ cacy and cost-
effectiveness of treatments. This study reviews, in selected major markets worldwide, 
the impact of currently available predictive biomarkers on HTA in the context of the 
agency’s evidence requirements. METHODS: A broad review of biomarker tests used 
in HTA submissions in Europe, Australia, Canada, and the US was conducted; the 
